
Novo Nordisk shares fell sharply on Monday after its US rival Eli Lilly released positive trial results for a weight loss pill. This raised fears of increased competition in the lucrative obesity market. The drop in Novo Nordisk’s shares contributed to a broader decline in European markets.
The German share price index DAX saw a significant dip at the stock exchange in Frankfurt. In other news, Swiss insurers Helvetia and Baloise announced a merger. The deal is set to create Switzerland’s second-largest insurance group.
Market participants are also closely watching the eurozone consumer confidence report. The report is scheduled for release at 1400 GMT. Former President Donald Trump has added to the market’s volatility with his recent criticism of Federal Reserve Chair Jerome Powell.